Isocitrate Dehydrogenase

Current Location

19 Isocitrate Dehydrogenase Trials Near You

Power is an online platform that helps thousands of Isocitrate Dehydrogenase patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

HMPL-306 for Blood Cancers

Columbus, Ohio
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

75 Participants Needed

Olutasidenib + Temozolomide for Brain Tumors

Columbus, Ohio
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 39

60 Participants Needed

Multiple Therapies for Glioblastoma

Columbus, Ohio
This trial is testing various treatments for patients with newly diagnosed or returning brain cancer. It adjusts treatments based on how well patients are doing to find the most effective options. The goal is to improve survival rates by matching the best treatments to specific patient types.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

1030 Participants Needed

Eflornithine + Temozolomide for Glioblastoma

Cleveland, Ohio
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

66 Participants Needed

HMPL-306 for Isocitrate Dehydrogenase Deficiency

Lexington, Kentucky
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

90 Participants Needed

LY3410738 for Blood Cancers

Chicago, Illinois
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

260 Participants Needed

Debio 0123 + Temozolomide for Glioblastoma

Chicago, Illinois
This trial is testing a new drug called Debio 0123 combined with standard treatments for adults with aggressive brain cancer. It aims to find the best dose, ensure safety, and check if it works better than current treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

116 Participants Needed

Olaparib + Durvalumab for Solid Tumors

Toronto, Ontario
This is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to assess the efficacy of the drug combination via overall response rate and overall disease control rate. It is believed that giving olaparib and durvalumab together would be more useful when given to patients with IDH-mutated solid tumors than giving each drug alone.
No Placebo Group

Trial Details

Trial Status:Recruiting

58 Participants Needed

DSP-0390 for Brain Tumors

Saint Louis, Missouri
This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. The hypothesis is that DSP-0390 will accumulate in brain tumor tissue at pharmacologically relevant concentrations, and that alterations in cholesterol metabolism driven by mutant IDH will increase susceptibility to DSP-0390 and lead to tumor cell death.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

20 Participants Needed

ATRA + PD-1 Inhibitor for Brain Tumor

Philadelphia, Pennsylvania
This trial tests a combination of a vitamin A derivative and an immune-boosting drug in patients with recurring brain tumors. The treatment aims to normalize cancer cell behavior and enhance the immune system's ability to fight the tumor.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

55 Participants Needed

Topotecan for Brain Cancer

New York, New York
The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase mutation (IDH-mut). The secondary goal of the study is to study drug distribution and assess the tumor response to prolonged continuous CED of Topotecan. Convection Enhanced Delivery is a novel method of drug delivery that allows administration of a drug directly to the brain. In CED, a drug pump is placed under the skin in the chest or abdominal region. The pump is connected to a catheter that is tunneled underneath the skin to the brain. The tip of the catheter then infuses Topotecan directly onto the brain tumor. There will be a total of four treatment infusions over the course of 23-29 days, with a 5-7-day rest period between each infusion. Throughout this period, patients' health will be monitored through imaging, blood draws, and regular exams. At the end of the treatment period, the pump will be removed, followed by resection of the tumor. Patients will be followed for the duration of their lives. This is the investigator's second clinical trial studying CED of TPT in recurrent glioma. In the prior Phase 1b trial, chronic pulsatile CED safely and effectively delivered Topotecan to patients with IDH mutant recurrent Glioblastoma (WHO grade 4).
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1

6 Participants Needed

Ivosidenib for Acute Myeloid Leukemia

Boston, Massachusetts
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Prior Safety Data

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

75 Participants Needed

Niraparib for Recurrent Brain Cancer

Boston, Massachusetts
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. - This research study involves an experimental treatment called Niraparib.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

16 Participants Needed

Troriluzole for Recurrent Brain Cancer

Boston, Massachusetts
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

27 Participants Needed

Olutasidenib + Venetoclax + Azacitidine for Acute Myeloid Leukemia

Miami, Florida
The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. 2. Determine how well the combination treatment of olutasidenib, venetoclax, and azacitidine works compared to the usual chemotherapy treatment that people with this condition receive.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

16 Participants Needed

Molecular Imaging with MRI for Brain Cancer

Miami, Florida
MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

30 Participants Needed

Virus Therapy for Brain Tumors

Houston, Texas
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

36 Participants Needed

Niacin CRT for Glioblastoma

Calgary, Alberta
This study is evaluating whether a new drug called Niacin CRT™ can improve the survival of people with glioblastoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

59 Participants Needed

HP C13-aKG MRI for Brain Tumor

San Francisco, California
This trial uses a special imaging dye to help doctors see brain tumors more clearly on MRI scans. It focuses on patients with a specific type of brain tumor that may not respond well to typical treatments. The dye makes the tumors more visible, aiding in better measurement and understanding.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

40 Participants Needed

Why Other Patients Applied

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Isocitrate Dehydrogenase clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Isocitrate Dehydrogenase clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Isocitrate Dehydrogenase trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Isocitrate Dehydrogenase is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Isocitrate Dehydrogenase medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Isocitrate Dehydrogenase clinical trials?

Most recently, we added Topotecan for Brain Cancer, Olutasidenib + Venetoclax + Azacitidine for Acute Myeloid Leukemia and Ivosidenib for Acute Myeloid Leukemia to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Fort Worth, TX

29 Alzheimer's Disease Trials near Columbia, SC

Top Clinical Trials near Houma, LA

13 Glaucoma Trials near Raleigh, NC

Top Mesothelioma Clinical Trials

Top Clinical Trials near Greenwich, CT

Top Glioblastoma Clinical Trials near Kansas City, MO

Top Arthritis Clinical Trials near Cincinnati, OH

Top Clinical Trials near Aventura, FL

Top Kidney Failure Clinical Trials

Top Clinical Trials near Folsom, CA

8 Glaucoma Trials near Austin, TX

By Trial

Neurofeedback Mindfulness for Migraines

Baricitinib for Pediatric Hair Loss

Closed Loop DBS for Parkinson's Disease

Bictegravir + Lenacapavir for HIV

Personalized Immunotherapy for Advanced Cancers

SFDI Imaging for Scleroderma

Surgery or High-Dose Radiation for Metastatic Breast Cancer

Mirikizumab for Pediatric Crohn's Disease

Electric Toothbrush for Post-Oral Surgery Care in Cleft Lip/Palate Patients

Adherence Intervention for Breast Cancer Treatment Compliance

Speech Therapy with Biofeedback for Speech Sound Disorder

mpMRI vs TURBT for Bladder Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial